As PDL1-inhibitor has shown significant effects as a cancer therapy in clinical trials (Kim et al., 2020), it may also hold potential as immune therapy for periodontitis patients, especially in the case of immune-compromised patients. This evidence concerns the gene CD274 and periodontitis.